![GlobeNewswire by notified](/data/images/00959/7a30bdb6-8948-4948-a1b9-122a029a6a54-w_300_h_100.png)
Immunicum Announces Presentations at the European Hematology Association (EHA) 2021 Virtual Congress
Press Release
12 May 2021
Immunicum Announces Presentations at the European Hematology Association (EHA) 2021 Virtual Congress
Immunicum AB (publ; IMMU.ST) today announced that it will be presenting two posters on its off-the-shelf relapse vaccine DCP-001 at the EHA 2021 Virtual Congress, to be held from June 9-17, 2021. The accepted abstracts are now published on the conference website and accessible through www.ehaweb.org. The presentations include interim immunological results from the Phase II ADVANCE II study, demonstrating DCP-001’s ability to induce immune responses to a broad range of tumor-associated antigens in acute myeloid leukemia (AML) patients, as well as preclinical results of enhanced efficacy when combining DCP-001 with established AML treatment regimens.
“From the interim clinical data published in the abstract today, we are excited to see that DCP-001 induces a range of detectable immune responses in AML patients participating in our ongoing ADVANCE II study,” said Jeroen Rovers, Chief Medical Officer at Immunicum.“These results demonstrate that DCP-001 has the ability to activate the immune system and induce a broad cellular anti-tumor response, with the aim to ultimately prevent leukemia relapse in these patients. We continue to enroll patients in ADVANCE II and remain on track to present more efficacy results before the end of this year.”
The clinical abstract on DCP-001 (EP458) in the ongoing ADVANCE II clinical study covers data on patients who completed the full vaccination schedule and demonstrates that patients treated with DCP-001 present with inflammation and infiltration of CD4+ and CD8+ T cells at the site of injection. In the blood of patients, an increase in CD8+ T cells and specific immune responses to known tumor-associated antigens present in DCP-001, such as PRAME and WT-1, were observed. At the data cutoff, DCP-001 was able to successfully convert the measurable residual disease (MRD) status from positive to negative in 2 out of 5 patients with immune response data available. In these patients, multiple antigenic responses and high levels of infiltrating immune cells at the injection site were observed.
The second abstract (EP403) covers preclinical data on the combination of DCP-001 with the established AML treatment agents venetoclax (VEN) and 5-azacitidine (5-AZA). Humanized immunocompetent mice were assigned to the triple combination of DCP-001 with VEN and 5-AZA, DCP-001 alone, VEN and 5-AZA or the control group. Results demonstrated that all treatment groups reduced tumor growth as compared to the control group and that average tumor volume was significantly reduced in the triple combination group as compared to all other groups, supporting the use of DCP-001 as add-on treatment with established AML treatment regimens in AML patients.
Abstracts for the EHA 2021 Virtual Congress were published today and are available through this link. E-posters will be available for registered attendees through the Virtual Congress platform starting Friday, June 11, 09:00 CEST.
Details on the presentations are as follows:
Title: | Induced systemic T-cell specific responses the multiple tumor-associated antigens after allogenic leukemia-derived dendritic cell vaccine DCP-001 in AML patients with persistent MRD |
Abstract #: | EP458 |
Session Topic: | Acute Myeloid Leukemia – Clinical |
Title: | Enhanced efficacy of the DCP-001 relapse vaccine when combined with Venetoclax and 5-Azaciticidine in a humanised immunocompetent mouse model of AML |
Abstract #: | EP403 |
Session Topic: | Acute myeloid leukemia - Biology & Translational Research |
For more information, please contact:
Erik Manting
Chief Executive Officer
Telephone: +31 713 322 627
E-mail: ir@immunicum.com
Investor Relations
Sijme Zeilemaker
Head of Investor Relations & Corporate Communication
Telephone: +46 8 732 8400
E-mail: ir@immunicum.com
Media Relations
Eva Mulder and Sophia Hergenhan
Trophic Communications
Telephone: +49 175 222 57 56
E-mail: immu@trophic.eu
About Immunicum AB (publ)
Immunicum is leveraging its unparalleled expertise in dendritic cell biology to develop novel, off-the-shelf, cell-based therapies for solid and blood-borne tumors. With complementary therapeutic approaches in Phase II clinical development that are based on intratumoral priming and cancer relapse vaccination, the company aims to improve survival outcomes and quality of life for a broad population of cancer patients. Based in Sweden and the Netherlands, Immunicum is publicly traded on the Nasdaq Stockholm. www.immunicum.com
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Iveco Group signs a 150 million euro term loan facility with Cassa Depositi e Prestiti to support investments in research, development and innovation11.6.2024 12:00:00 CEST | Press release
Turin, 11th June 2024. Iveco Group N.V. (EXM: IVG), a global automotive leader active in the Commercial & Specialty Vehicles, Powertrain and related Financial Services arenas, has successfully signed a term loan facility of 150 million euros with Cassa Depositi e Prestiti (CDP), for the creation of new projects in Italy dedicated to research, development and innovation. In detail, through the resources made available by CDP, Iveco Group will develop innovative technologies and architectures in the field of electric propulsion and further develop solutions for autonomous driving, digitalisation and vehicle connectivity aimed at increasing efficiency, safety, driving comfort and productivity. The financed investments, which will have a 5-year amortising profile, will be made by Iveco Group in Italy by the end of 2025. Iveco Group N.V. (EXM: IVG) is the home of unique people and brands that power your business and mission to advance a more sustainable society. The eight brands are each a
DSV, 1115 - SHARE BUYBACK IN DSV A/S11.6.2024 11:22:17 CEST | Press release
Company Announcement No. 1115 On 24 April 2024, we initiated a share buyback programme, as described in Company Announcement No. 1104. According to the programme, the company will in the period from 24 April 2024 until 23 July 2024 purchase own shares up to a maximum value of DKK 1,000 million, and no more than 1,700,000 shares, corresponding to 0.79% of the share capital at commencement of the programme. The programme has been implemented in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (“MAR”) (save for the rules on share buyback programmes set out in MAR article 5) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. Trading dayNumber of shares bought backAverage transaction priceAmount DKKAccumulated trading for days 1-25478,1001,023.01489,100,86026:3 June 20247,0001,050.597,354,13027:4 June 20245,0001,055.705,278,50028:6 June20243,0001,096.273,288,81029:7 June 20244,0001,106.174,424,68
Landsbankinn hf.: Offering of covered bonds11.6.2024 11:16:36 CEST | Press release
Landsbankinn will offer covered bonds for sale via auction held on Thursday 13 June at 15:00. An inflation-linked series, LBANK CBI 30, will be offered for sale. In connection with the auction, a covered bond exchange offering will take place, where holders of the inflation-linked series LBANK CBI 24 can sell the covered bonds in the series against covered bonds bought in the above-mentioned auction. The clean price of the bonds is predefined at 99,594. Expected settlement date is 20 June 2024. Covered bonds issued by Landsbankinn are rated A+ with stable outlook by S&P Global Ratings. Landsbankinn Capital Markets will manage the auction. For further information, please call +354 410 7330 or email verdbrefamidlun@landsbankinn.is.
Relay42 unlocks customer intelligence with a new insights and reporting module, powered by Amazon QuickSight11.6.2024 11:00:00 CEST | Press release
AMSTERDAM, June 11, 2024 (GLOBE NEWSWIRE) -- Relay42, a leading European Customer Data Platform (CDP), is leveraging Amazon QuickSight to power its new real-time customer intelligence, reporting, and dashboard module. Harnessing the breadth and quality of customer data, the new Insights module empowers marketing teams to dive deep into customer behaviors and gain invaluable insights into the performance of their marketing programs across all online, offline, paid, and owned marketing channels. Preview of the Relay42 Insights module, in pre-beta version Key capabilities of the Relay42 Insights module include: Deep insights into customer behaviors: With the Relay42 Insights module, marketers can ask unlimited questions about their data and gain a deeper understanding of how to serve their customers more effectively. Simplicity with AI-powered querying: Marketers can use artificial intelligence to query their data using natural language search, reducing the reliance on data scientists. Us
Metasphere Labs Announces X Spaces Event on the Topic of Green Bitcoin Mining and Sound Money for Sustainability11.6.2024 10:30:00 CEST | Press release
VANCOUVER, British Columbia, June 11, 2024 (GLOBE NEWSWIRE) -- Metasphere Labs Inc. (formerly Looking Glass Labs Ltd., "Metasphere Labs" or the "Company") (Cboe Canada: LABZ) (OTC: LABZF) (FRA: H1N) is thrilled to announce an engaging Twitter Spaces event on Green Bitcoin mining, energy markets, and sustainability on July 3, 2024 at 2 p.m. ET. Follow us on X at MetasphereLabs for updates and to join the event. What We'll Discuss Bitcoin Mining Basics: Understand the fundamentals of Bitcoin mining.Energy Market Dynamics: Explore how Bitcoin mining interacts with energy markets.Sustainable Innovations: Learn about our efforts to promote sustainability in Bitcoin mining.Sound Money: Discover how tamper-proof currency can enhance stability.Efficient Payment Rails: See how fast, neutral payment systems support humanitarian projects.Carbon Footprint: Compare Bitcoin's environmental impact with traditional banking. "We're excited to host this event and dive into the critical topics of Bitcoin